Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC-Reference-Cited by-同舟云学术

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC

Published:2020-01-16 Issue:5 Volume:9 Page:1683-1693
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Wan Ning¹²^ORCID,Zhang Tian‐tian³⁴⁵,Hua Si‐hua³,Lu Zi‐luo³,Ji Bo¹,Li Li‐xia⁶,Lu Li‐qing¹,Huang Wen‐jie⁷,Jiang Jie³⁴⁵⁸,Li Jian¹

Affiliation:

1. Department of Pharmacy General Hospital of Southern Theater Command Guangzhou Guangdong China

2. Guangzhou Huabo Biopharmaceutical Research Institute Guangzhou Guangdong China

3. College of Pharmacy Jinan University Guangzhou Guangdong China

4. The First Affiliated Hospital of Jinan University Guangzhou Guangdong China

5. International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE) Jinan University Guangzhou Guangdong China

6. Department of Oncology General Hospital of Southern Theater Command Guangzhou Guangdong China

7. Department of Respiratory Medicine General Hospital of Southern Theater Command Guangzhou Guangdong China

8. Dongguan Institute of Jinan University Dongguan China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2793

Reference42 articles.

1. GLOBOCAN 2012 vol 1.1.http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed August 14 2017.

2. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

3. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

4. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Efficacy, safety, and cost-effectiveness of pembrolizumab versus chemotherapy for patients with advanced non-small cell lung cancer: a real-world study;2024-04-25

2. Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review;Cancers;2024-02-29

3. Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer;Current Medical Research and Opinion;2024-01-22

4. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview;Critical Reviews in Oncology/Hematology;2024-01

5. Systematic Evaluation of Cost-Utility Analysis of Immunotherapy Combined with Chemotherapy for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2024